Marburgvirus Infections (Marburg Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 99 Published: April 05, 2022 Report Code: GDGMDHC22169IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech.org

The Marburgvirus Infections pipeline market report provides a comprehensive overview on the therapeutics under development for Marburgvirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Marburgvirus Infections and features dormant and discontinued projects.

Key Targets in the Marburgvirus Infections Pipeline Drugs Market

In the Marburgvirus Infections pipeline drugs market the key targets are Ebola virus Matrix Protein VP40, 70 kDa Ribosomal Protein S6 Kinase, Cathepsin L1, Glycoprotein, Hepatitis A Virus Cellular Receptor 1, Interferon Alpha, Interferon Beta, Interferon Gamma, Mannosyl Oligosaccharide Glucosidase, and Marburg Virus Membrane Associated Protein VP24.

Marburgvirus Infections Pipeline Drugs Market, by Targets

Marburgvirus Infections Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Marburgvirus Infections Pipeline Drugs Market

70 kDa Ribosomal Protein S6 Kinase Inhibitor has the highest number of pipeline products followed by Cathepsin L1 Inhibitor, Ebola virus Matrix Protein VP40 Inhibitor, Hepatitis A Virus Cellular Receptor 1 Inhibitor, Interferon Alpha Activator, Interferon Beta Activator, Interferon Gamma Activator, Mannosyl Oligosaccharide Glucosidase Inhibitor, Marburg Virus Membrane Associated Protein VP24 Inhibitor, and Na+/K+ Exchanging ATPase Inhibitor.

Marburgvirus Infections Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Marburgvirus Infections pipeline drugs market are inhalational, intramuscular, oral, nasal, intravenous, and transdermal. Inhalational has the maximum number of pipeline products.

Marburgvirus Infections Pipeline Drugs Market Analysis, by RoA

Marburgvirus Infections Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Marburgvirus Infections Pipeline Drugs Market

The key molecule types in the Marburgvirus Infections pipeline drugs market are small molecule, recombinant vector vaccine, subunit vaccine, vaccine, monoclonal antibody, antibody, protein, and recombinant protein.

Marburgvirus Infections Pipeline Drugs Market, by Molecule Type

Marburgvirus Infections Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Marburgvirus Infections Pipeline Drugs Market

The major companies in the Marburgvirus Infections pipeline drugs market are Integrated BioTherapeutics Inc, Emergent BioSolutions Inc, AIkido Pharma Inc, Intervir Therapeutics, Soligenix Inc, TFF Pharmaceuticals Inc, AlphaVax Inc, ANP Technologies Inc, and Auro Vaccines LLC.

Marburgvirus Infections Pipeline Drugs Market, by Major Companies

Marburgvirus Infections Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Marburgvirus Infections Pipeline Drugs Market Overview

Key Targets Ebola virus Matrix Protein VP40, 70 kDa Ribosomal Protein S6 Kinase, Cathepsin L1, Glycoprotein, Hepatitis A Virus Cellular Receptor 1, Interferon Alpha, Interferon Beta, Interferon Gamma, Mannosyl Oligosaccharide Glucosidase, and Marburg Virus Membrane Associated Protein VP24
Key Mechanisms of action 70 kDa Ribosomal Protein S6 Kinase Inhibitor, Cathepsin L1 Inhibitor, Ebola virus Matrix Protein VP40 Inhibitor, Hepatitis A Virus Cellular Receptor 1 Inhibitor, Interferon Alpha Activator, Interferon Beta Activator, Interferon Gamma Activator, Mannosyl Oligosaccharide Glucosidase Inhibitor, Marburg Virus Membrane Associated Protein VP24 Inhibitor, and Na+/K+ Exchanging ATPase Inhibitor.
Key Routes of Administration Inhalational, Intramuscular, Oral, Nasal, Intravenous, and Transdermal
Key Molecule Types Small Molecule, Recombinant Vector Vaccine, Subunit Vaccine, Vaccine, Monoclonal Antibody, Antibody, Protein, and Recombinant Protein
Major Companies Integrated BioTherapeutics Inc, Emergent BioSolutions Inc, AIkido Pharma Inc, Intervir Therapeutics, Soligenix Inc, TFF Pharmaceuticals Inc, AlphaVax Inc, ANP Technologies Inc, and Auro Vaccines LLC

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections
  • The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Marburgvirus Infections therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Marburgvirus Infections therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Marburgvirus Infections

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

AIkido Pharma Inc

AlphaVax Inc

ANP Technologies Inc

Auro Vaccines LLC

BioCryst Pharmaceuticals Inc

Collaborations Pharmaceuticals Inc

Emergent BioSolutions Inc

Emergex Vaccines Holding Ltd

Fab’entech SA

Flow Pharma Inc

Fox Chase Chemical Diversity Center Inc

GeoVax Labs Inc

Globavir Biosciences Inc

Greffex Inc

Helix Biogen Institute

Integrated BioTherapeutics Inc

Intervir Therapeutics

Mapp Biopharmaceutical Inc

Microbiotix Inc

Phoenix Biotechnology Inc

ReVacc Biotech

Rodos BioTarget GmbH

Selva Therapeutics Inc

Soligenix Inc

TFF Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Overview

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Companies Involved in Therapeutics Development

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drug Profiles

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Dormant Projects

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Discontinued Products

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by AIkido Pharma Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by AlphaVax Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by ANP Technologies Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Auro Vaccines LLC, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Collaborations Pharmaceuticals Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Emergex Vaccines Holding Ltd, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Fab’entech SA, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Flow Pharma Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Fox Chase Chemical Diversity Center Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by GeoVax Labs Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Globavir Biosciences Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Greffex Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Helix Biogen Institute, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Integrated BioTherapeutics Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Intervir Therapeutics, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Mapp Biopharmaceutical Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Microbiotix Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Phoenix Biotechnology Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by ReVacc Biotech, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Rodos BioTarget GmbH, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Selva Therapeutics Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Soligenix Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by TFF Pharmaceuticals Inc, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Dormant Projects, 2022

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Dormant Projects, 2022 (Contd..1)

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

In the Marburgvirus Infections pipeline drugs market the key targets are Ebola virus Matrix Protein VP40, 70 kDa Ribosomal Protein S6 Kinase, Cathepsin L1, Glycoprotein, Hepatitis A Virus Cellular Receptor 1, Interferon Alpha, Interferon Beta, Interferon Gamma, Mannosyl Oligosaccharide Glucosidase, and Marburg Virus Membrane Associated Protein VP24.

In the Marburgvirus Infections pipeline drugs market the key mechanisms of action are 70 kDa Ribosomal Protein S6 Kinase Inhibitor, Cathepsin L1 Inhibitor, Ebola virus Matrix Protein VP40 Inhibitor, Hepatitis A Virus Cellular Receptor 1 Inhibitor, Interferon Alpha Activator, Interferon Beta Activator, Interferon Gamma Activator, Mannosyl Oligosaccharide Glucosidase Inhibitor, Marburg Virus Membrane Associated Protein VP24 Inhibitor, and Na+/K+ Exchanging ATPase Inhibitor.

The key routes of administration in the Marburgvirus Infections pipeline drugs market are Inhalational, Intramuscular, Oral, Nasal, Intravenous, and Transdermal.

The key molecule types in the Marburgvirus Infections pipeline drugs market are small molecule, recombinant vector vaccine, subunit vaccine, vaccine, monoclonal antibody, antibody, protein, and recombinant protein.

In the Marburgvirus Infections pipeline drugs market the major companies are Integrated BioTherapeutics Inc, Emergent BioSolutions Inc, AIkido Pharma Inc, Intervir Therapeutics, Soligenix Inc, TFF Pharmaceuticals Inc, AlphaVax Inc, ANP Technologies Inc, and Auro Vaccines LLC.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.